The EPO published international patent application EP4310079A1 for estrogen receptor antagonists, filed by Shenzhen Forward Pharmaceuticals Co., Limited (China). The application covers specific heterocyclic chemical compounds with potential therapeutic applications in cancer treatment, classified under C07D 498/04 and C07D 519/00 with pharmaceutical composition applications under A61K 31/4738 and A61P 35/00. The designated contracting states include all EPC member states (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR).

This is a patent publication notice, not a regulatory action imposing compliance obligations. No deadlines, fees, or required actions arise from this publication. Pharmaceutical companies developing similar compounds should review this publication to assess potential freedom-to-operate considerations or opportunities for licensing negotiations with the applicant.